Last updated: 11/07/2018 19:25:47
A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Effect of 12 Months Treatment With Salmeterol (50mcg bd), Delivered via the DISKUS* Inhaler, on the Incidence of Moderate and Severe Exacerbations in Subjects With Chronic Obstructive Pulmonary ...
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Effect of 12 Months Treatment With Salmeterol (50mcg bd), Delivered via the DISKUS* Inhaler, on the Incidence of Moderate and Severe Exacerbations in Subjects With Chronic Obstructive Pulmonary ...
Trial description: A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Effect of 12 Months Treatment With Salmeterol (50mcg bd), Delivered via the DISKUS* Inhaler, on the Incidence of Moderate and Severe Exacerbations in Subjects With Chronic Obstructive Pulmonary ...
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Stockley R, Davis EA, Sondhi S, Rice L, on behalf of an International Study Group. Salmeterol provides sustained health status improvement over 12 months in patients with COPD. Abstract presented at COPD 3, Birmingham, June 12-14th 13 2002
Stockley R, Davis EA, Sondhi S, Rice L. Salmeterol provides sustained health status improvement over 12 months in patients with COPD. Eur Respir J 2002; 20 (suppl 38): 241s (P1567).
Stockley R, Rice L, Chopra N. Salmeterol added to usual therapy gives a rapid improvement in lung function that is sustained at 6 and 12 months in patients with COPD. Am J Respir Crit Care Med 2003; 167 (7): A93.
Stockley R, Rice L, Chopra N. Salmeterol added to usual therapy significantly reduces the frequency of moderate/severe exacerbations in patients with COPD. Am J Respir Crit Care Med 2003; 167 (7): A229
Stockley RA, Chopra N, on behalf of an International Study Group. Salmeterol, added to usual therapy, is an effective bronchodilator over 12 months of treatment in chronic obstructive pulmonary disease (COPD). Abstract presented at COPD 3, Birmingham, June 12-14th 2002
Stockley RA, Chopra N. Salmeterol, added to usual therapy, is an effective bronchodilator over 12 months of treatment in chronic obstructive pulmonary disease (COPD). Eur Respir J 2002; 20 (suppl 38): 241s (P1568)
Stockley RA, Rice L, Chopra N. A 12 month study to investigate the effects of salmeterol on the incidence of moderate and severe exacerbations in patients with chronic obstructive pulmonary disease (COPD). Abstract presented at COPD 3, Birmingham, June 12-14th 2002
Medical condition
Pulmonary Disease, Chronic Obstructive
Product
salmeterol
Collaborators
Not applicable
Study date(s)
April 2000 to October 2001
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2001-27-10
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website